The Advisory Board Company Reports Fiscal Year 2010 Second Quart...(ase and the accompanying tables include ...),Health

Date:11/2/2009

ase and the accompanying tables include a discussion of adjusted EBITDA, adjusted net income, and adjusted earnings per diluted share, which are non-GAAP financial measures provided as a complement to the results provided in accordance with accounting principles generally accepted in the United States of America ("GAAP"). As used in this release, the term "Adjusted EBITDA" refers to a financial measure that we define as earnings before other income, net, which includes interest income and foreign currency losses and gain; income taxes; depreciation and amortization; and one-time non-cash charges associated with the write-off of capitalized software and the cancellation of certain stock options. The term "Adjusted net income" refers to net income excluding the net of tax effect of one-time non-cash charges associated with the write-off of capitalized software and the cancellation of certain stock options. "Adjusted earnings per diluted share" refers to net income per share excluding the per share effect, net of tax, of one-time non-cash charges associated with the write-off of capitalized software and the cancellation of certain stock options. These non-GAAP measures may be considered in addition to financial measures prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP measures or results. Furthermore, we intend to continue to provide these non-GAAP financial measures as part of our future earnings discussions and, therefore, the inclusion of these non-GAAP financial measures will provide consistency in our financial reporting. We believe that adjusted EBITDA, adjusted net income and adjusted diluted earnings per share are relevant and useful information for our investors. We use these non-GAAP financial measures for internal budgeting and other managerial purposes because it enables the Company's management to evaluate projected operating results on a basis that allows for comparability without regard to changes ar
'/>"/>

SOURCE The Advisory Board Company Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Related medicine news :

1. Important new novel 2009 H1N1 flu advisory for cardiopulmonary transplantation
2. The Advisory Board Company Schedules Second Quarter Conference Call for November 2, 2009
3. Bionovo Adds Dr. Debu Tripathy to Their Medical Advisory Board
4. World-first mental health media initiative announces inaugural Advisory Group
5. Tranziger Announces Formation of Global Advisory & Development Team
6. FDA Advisory Committee Recommends Approval of PEGINTRON(R) for the Adjuvant Treatment of Stage III Malignant Melanoma
7. William Fuchs Named to PerfectServe Advisory Board
8. Data Strategy Invited to Become a Member of VMware's Partner Technical Advisory Board (PTAB)
9. Star Scientific Breaks New Ground, Plans FDA Filing for Approval of First Modified Risk Tobacco Product; Nominates Curtis Wright, MD, MPH for FDA Advisory Committee
10. FDA Advisory Committee Unanimously Recommends Approval of XIAFLEX(TM) for Treatment of Dupuytrens Disease
11. Robert Fanning Named to PerfectServe Advisory Board